Going Green First Thing, Low Float (Nasdaq: CTOR) Could Drum Up Some Serious Buzz

Citius Oncology, Inc. (Nasdaq: CTOR) just turned green at the bell. Have it on your radar?

*Sponsored Going Green First Thing, Low Float (Nasdaq: CTOR) Could Drum Up Some Serious Buzz *Get Our Updates Faster—Tap Here To Receive SMS Alerts* December 19th Greetings, Friend! Citius Oncology, Inc. (Nasdaq: CTOR) just turned green at the bell. Have it on your radar? If not, here's a few potential catalysts to consider: 1.) It was only earlier this month that CTOR launched commercialization for its game-changing therapy, LYMPHIR. 2.) To aid the commercial launch, the company just closed a registered direct offering and a private placement. 3.) Volatility potential may be heightened daily due to a low float of fewer than 4Mn shares. Those are only 3 right there. You'll find more in the report below. Spend a second reviewing my initial report on (Nasdaq: CTOR) below and consider putting this pharma profile on your radar. ----- A little known pharma company, still somewhat under the radar, just closed an $18Mn registered direct offering alongside a private placement—both executed under Nasdaq regulations. The fresh proceeds will aim to help speed up the commercial rollout of its newly approved treatment, LYMPHIR, focused on meeting urgent patient needs. This announcement’s timing highlights the company’s drive to deliver cutting-edge therapies efficiently. As commercialization advances, the financing signals a key inflection point for a company intent on performance and lasting growth in immunotherapy. And with a low float— which means volatility potential could be heightened—and an analyst target projecting strong triple-digit upside, this lesser-known Nasdaq profile sits firmly at the top of my watchlist: Citius Oncology, Inc. (Nasdaq: CTOR) Citius Oncology, Inc. is a platform to develop and commercialize novel targeted oncology therapies. In August 2024, its primary asset, LYMPHIR, was approved by the FDA for the treatment of adults with relapsed or refractory Stage I–III CTCL who had had at least one prior systemic therapy. Management estimates the initial market for LYMPHIR currently exceeds $400Mn, is growing, and is underserved by existing therapies. (1) Company Overview - Citius Oncology, Inc. (Nasdaq: CTOR) Biopharmaceutical company focused on developing and commercializing innovative targeted oncology therapies #1. Lead product, LYMPHIR, FDA approved August 2024 Orphan Indication: treatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy 12-year BLA exclusivity First new systemic CTCL therapy since 2018  #2. Commercialization has officially launched as of December 2025 #3. Estimated $400Mn+ addressable U.S. market with growth opp's(1) #4. Publicly traded on NASDAQ since August 2024 (Ticker: CTOR) Citius Oncology, Inc. (Nasdaq: CTOR) Preps For Launch Of Lymphir In Q4 2025 Commercial launch readiness nearing completion through disciplined financial strategy What Exactly Is Cutaneous T-Cell Lymphoma (CTCL)? Considered to be incurable, CTCL is a Subgroup of Non-Hodgkin Lymphomas (NHL) that can be Indolent or Aggressive and is Driven by Malignant T Cells Patients with persistent or recurrent CTCL require systemic therapy. 1. Dummer R, et al. Nat Rev Dis Primers. 2021;7(1):61. 2. Rangoonwala, HI and Cascella M. 2022, StatPearls Publishing: Treasure Island, FL. 3. Cleveland Clinic. Cutaneous T-Cell Lymphoma. 2023. Available from: https0://my.clevelandclinic.org/health/diseases/17940-cutaneous-t-cell-lymphoma 4. Hristov AC, et al. Am J Hematol. 2019;94(9):1027-1041 Convincing Clinical Findings  LYMPHIR addresses CTCL’s heavy Quality of Life burden 1. Objective Response is Complete Response and Partial Response according to the ISCL/EORTC Global Response Score. 2. In the Primary Efficacy Analysis set, 84.4% (54/64) of skin evaluable subjects had a decrease in skin tumor burden, with 48.4% subjects with ≥50% reduction in skin tumor burden. Complete clearing of skin disease (skin CR) was observed in 12.5% (8/64)subjects. 3. The duration of response (DOR) was at least 6 months for 52% of responders and at least 12 months for 20% of responders (25/69 patients). Potential For Expansion Beyond Cutaneous T-cell Lymphoma (CTCL) University of Pittsburgh: an investigator-initiated trial is underway to evaluate LYMPHIR for potential use as an immuno-oncology therapy in combination with KEYTRUDA® in patients with recurrent or metastatic solid tumors (NCT05200559) Encouraging preliminary results of interim analysis: 15 evaluable patients showed 27% ORR; 33% Clinical Benefit Rate; median Progression Free Survival of 57 weeks (for patients that achieved a clinical benefit) The data supports further evaluation of this combination across a broader range of solid tumor types. Phase 1 Preliminary study data (n=25) anticipated Q4 2025/Q1 2026. University of Minnesota: LYMPHIR in combination with CAR T therapies (NCT04855253) Phase 1 study to evaluate the potential benefit of LYMPHIR given prior to CAR T therapy in patients with high risk relapsed/refractory B-cell lymphomas. Preliminary study results anticipated Q1 2026. Logical label expansion potential in PTCL where there is a high unmet need and no curative therapies 1. KEYTRUDA is a registered trademark of Merck & Co., Inc. KYMRIAH is a registered trademark of Novartis Pharmaceuticals Corporation. Find Sources And More Key Details Here: CTOR Presentation. ----- 5 Potential Catalysts Put (Nasdaq: CTOR) Atop Monday's Watchlist #1. Could A Low Float (Under 4Mn Shares) Create The Potential For A Volatile Environment? According to the Yahoo Finance website, CTOR has a very low float. In fact, the website reports this profile to have approximately 3.44Mn shares in its float. Why is that important? It's important on one crucial level. Volatility potential. Could a commercial launch announcement towards the end of 2025 provide a breakout spark when paired with this volatility potential? #2. A Strong Analyst Target May Be Suggesting Serious Upside Potential. Over at the Maxim Group website, analyst Michael Okunewitch is providing CTOR with a $6 target. From Thursday's closing valuation, that target suggests CTOR could have upside potential over 400%.  #3. Citius Oncology Advances Growth Through Strategic $18Mn Dual Financing. Citius Oncology successfully closed concurrent registered direct and private placement offerings totaling $18Mn, both priced at-the-market under Nasdaq rules. The company plans to use the proceeds to fund the commercial launch of its newly approved therapy, LYMPHIR, and strengthen its working capital. This timely financing underscores Citius Oncology’s strong execution, growth focus, and commitment to advancing innovative cancer treatments. #4. Citius Oncology Strengthens Market Position With National Launch Of LYMPHIR Immunotherapy. Citius Oncology recently announced the full U.S. commercial launch of LYMPHIR™, an FDA-approved IL-2 receptor-directed immunotherapy for adults with relapsed or refractory Stage I–III cutaneous T-cell lymphoma (CTCL). This landmark launch marks Citius’s first marketed product and a major growth driver. With a $400Mn U.S. CTCL market opp., LYMPHIR positions Citius for success in oncology innovation and shareholder value creation. #5. Citius Oncology Expands LYMPHIR Global Reach Through Strategic Middle East Partnership. Citius Oncology announced an exclusive distribution agreement with Turkey-based Er-Kim İlaç Sanayi ve Ticaret A.Ş. ("Er-Kim") to expand LYMPHIR™ access across Turkey and six Gulf nations, including Saudi Arabia and the UAE. This collaboration brings LYMPHIR, an FDA-approved IL-2 receptor-directed therapy for relapsed or refractory CTCL, to 19 international markets through Named Patient Programs.  The partnership highlights Citius’s growing global footprint and commitment to delivering innovative cancer treatments. With Er-Kim’s regional expertise, Citius strengthens its international presence and accelerates LYMPHIR’s worldwide patient impact. ----- We're officially kicking-off coverage on Citius Oncology, Inc. (Nasdaq: CTOR). Be on watch for updates coming your way shortly. Talk again soon. All the best, Dane James Editor Market Pulse Today (Remember: St-ock Prices Could Be Significantly Lower Now From The Original Dates I Provided.) *MarketPulseToday.com (“MarketPulseToday” or “MPT” ) is owned by Thousand Sun Media LLC, MPT is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MPT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between Thousand Sun Media LLC and TD Media LLC, Thousand Sun Media LLC has been hired for a period beginning on 12/19/2025 and ending on 12/19/2025 to publicly disseminate information about (CTOR:US) via digital communications. Under this agreement, Thousand Sun Media LLC has been paid seven thousand five hundred USD ("Funds"). To date, including under the previously described agreement, Thousand Sun Media LLC has been paid fifteen thousand USD ("Funds"). These Funds were part of the funds that TD Media LLC received from a third party who did not receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither Thousand Sun Media LLC, TD Media LLC and their member own shares of (CTOR:US). Please see important disclosure information here: https://marketpulsetoday.com/disclosure/ctor-oypis/#details

Market Pulse Today | 1314 E LAS OLAS BLVD UNIT #2170 | FORT LAUDERDALE, FL 33301 US Unsubscribe | Update Profile | Our Privacy Policy | Constant Contact Data Notice